Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell based immunotherapies, for hematologic and solid tumor cancers, the analyst tells investors in a research note. The firm says the company could launch MT-601 in diffuse large B-cell lymphoma in 2027, and estimates MT-601 could result in $680.5M in product sales by 2030. It projects Marker will be earnings and operating cash flow positive starting in 2028.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics files to sell 10.06M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Marker Therapeutics sells 5.03M shares at $3.20 in private placement
- Marker Therapeutics provides update on MT-601 patients
- Marker Therapeutics awarded $9.5M grant from CPRIT